Next Article in Journal
Mercury-Supported Biomimetic Membranes for the Investigation of Antimicrobial Peptides
Previous Article in Journal
Asymmetric Synthesis of Spirocyclic 2-Benzopyrans for Positron Emission Tomography of σ1 Receptors in the Brain
Previous Article in Special Issue
Glibenclamide for the Treatment of Acute CNS Injury
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2014, 7(2), 113-135; doi:10.3390/ph7020113

From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy

Department of Medicinal Chemistry, Intra-cellular Therapies Inc. 3960 Broadway, New York, NY 10032, USA
Department of Organic Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel
Abital Pharma Pipeline Ltd., Tel Aviv 6789141, Israel
Author to whom correspondence should be addressed.
Received: 16 December 2013 / Revised: 13 January 2014 / Accepted: 17 January 2014 / Published: 23 January 2014
(This article belongs to the Special Issue CNS-Drugs and Therapy)
View Full-Text   |   Download PDF [389 KB, uploaded 23 January 2014]   |  


Brain network dysfunction in Alzheimer’s disease (AD) involves many proteins (enzymes), processes and pathways, which overlap and influence one another in AD pathogenesis. This complexity challenges the dominant paradigm in drug discovery or a single-target drug for a single mechanism. Although this paradigm has achieved considerable success in some particular diseases, it has failed to provide effective approaches to AD therapy. Network medicines may offer alternative hope for effective treatment of AD and other complex diseases. In contrast to the single-target drug approach, network medicines employ a holistic approach to restore network dysfunction by simultaneously targeting key components in disease networks. In this paper, we explore several drugs either in the clinic or under development for AD therapy in term of their design strategies, diverse mechanisms of action and disease-modifying potential. These drugs act as multi-target ligands and may serve as leads for further development as network medicines.
Keywords: memantine; nitromemantine; NMDA antagonist; M30; M30D; AChE-MAO-A/B inhibitor; chelator; Ginkgo biloba memantine; nitromemantine; NMDA antagonist; M30; M30D; AChE-MAO-A/B inhibitor; chelator; Ginkgo biloba
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Zheng, H.; Fridkin, M.; Youdim, M. From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy. Pharmaceuticals 2014, 7, 113-135.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top